Halozyme Therapeutics, Inc. $HALO Shares Sold by Snyder Capital Management L P

Snyder Capital Management L P reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 19.5% during the 3rd quarter, Holdings Channel.com reports. The firm owned 2,733,844 shares of the biopharmaceutical company’s stock after selling 663,853 shares during the period. Halozyme Therapeutics makes up approximately 3.8% of Snyder Capital Management L P’s portfolio, making the stock its 4th largest position. Snyder Capital Management L P’s holdings in Halozyme Therapeutics were worth $200,500,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in HALO. Empowered Funds LLC purchased a new stake in Halozyme Therapeutics during the first quarter worth about $755,000. Acadian Asset Management LLC purchased a new stake in shares of Halozyme Therapeutics during the 1st quarter worth approximately $195,000. Atria Investments Inc boosted its stake in shares of Halozyme Therapeutics by 8.6% during the 2nd quarter. Atria Investments Inc now owns 12,513 shares of the biopharmaceutical company’s stock worth $651,000 after acquiring an additional 986 shares in the last quarter. EFG Asset Management North America Corp. increased its stake in Halozyme Therapeutics by 1.3% in the 2nd quarter. EFG Asset Management North America Corp. now owns 104,439 shares of the biopharmaceutical company’s stock valued at $5,432,000 after purchasing an additional 1,347 shares in the last quarter. Finally, Cetera Trust Company N.A increased its stake in Halozyme Therapeutics by 7.4% in the 2nd quarter. Cetera Trust Company N.A now owns 6,200 shares of the biopharmaceutical company’s stock valued at $323,000 after purchasing an additional 425 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on HALO shares. The Goldman Sachs Group reissued a “sell” rating and issued a $56.00 target price on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Wells Fargo & Company increased their price objective on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. Wall Street Zen cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. Benchmark increased their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Finally, Weiss Ratings cut shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Tuesday, February 24th. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $78.56.

Halozyme Therapeutics Stock Up 0.9%

Shares of NASDAQ HALO opened at $70.02 on Thursday. The firm has a market cap of $8.26 billion, a P/E ratio of 28.12, a price-to-earnings-growth ratio of 0.28 and a beta of 0.98. The company has a debt-to-equity ratio of 43.89, a quick ratio of 3.66 and a current ratio of 4.66. Halozyme Therapeutics, Inc. has a 1 year low of $47.50 and a 1 year high of $82.22. The firm’s 50 day moving average price is $72.71 and its 200 day moving average price is $70.76.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The business had revenue of $451.77 million for the quarter, compared to analysts’ expectations of $446.13 million. During the same quarter last year, the company posted $1.26 earnings per share. The business’s quarterly revenue was up 51.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the sale, the director directly owned 40,123 shares in the company, valued at approximately $2,818,640.75. The trade was a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Helen Torley sold 10,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $70.21, for a total transaction of $702,100.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $53,905,833.80. This represents a 1.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 62,000 shares of company stock worth $4,545,200 over the last three months. Corporate insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.